NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005 (Third Quarter of Fiscal Year 2005)
Business Overview: NAI is engaged in the development, manufacturing, marketing, and distribution of nutritional supplements. The company operates primarily in the United States and Europe, with a significant portion of revenue derived from private label contract manufacturing.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Debt includes $1.22 million on line of credit and $4.07 million in term loans.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6% year-over-year (Q3) and 21% year-over-year (YTD). Growth was driven by a 28% increase in private label contract manufacturing sales, partially offset by a 22% decline in direct-to-consumer sales.
• Profitability Decline: Net income decreased 68% in Q3 and 4% YTD compared to the prior year. Gross margins compressed by 510 basis points in Q3 and 250 basis points YTD, primarily due to a sales mix shift toward lower-margin powder products and increased inventory reserves.
• Expense Management: Selling, general, and administrative (SG&A) expenses decreased 13% in Q3 but increased 2% YTD. Increases were driven by $323,000 in Sarbanes-Oxley compliance costs and $652,000 in regulatory certification costs (TGA), partially offset by reduced clinical study costs and lower management incentive payments.
• Cash Flow: Operating cash flow improved significantly to $1.86 million (YTD 2005) from a use of $0.96 million (YTD 2004), aided by better working capital management and a $0.96 million tenant improvement allowance from a landlord.
• Capital Expenditures: Investing cash outflows surged to $6.77 million (YTD 2005) from $2.02 million (YTD 2004), primarily due to the build-out of a new 160,000 sq. ft. facility in Vista, California.

Guidance, Outlook, and Risks

• Outlook: Management anticipates fiscal 2005 net sales will surpass record 2004 levels. Fourth-quarter sales and profitability are expected to be consistent with Q3 results. Regulatory costs are expected to decline in Q4, though direct-to-consumer brand development expenses may rise.
• Regulatory Status: The Therapeutic Goods Administration (TGA) of Australia completed a physical audit of U.S. facilities. Management expects to receive a certificate of compliance by the end of fiscal 2005, which is critical for maintaining international sales.
• Legal Contingency: A patent infringement lawsuit was filed by Novogen Research Pty. Ltd. in February 2005. NAI believes the claims are invalid and is seeking an out-of-court settlement; no damages have been claimed as of May 13, 2005.
• Customer Concentration: The company faces high concentration risk. Two customers accounted for 78% of YTD net sales, and one supplier accounted for 47% of raw material purchases in Q3.
• Accounting Changes: Implementation of SFAS 123R (Share-Based Payment) is required after June 15, 2005, which will likely increase reported expenses and reduce net income compared to current pro forma estimates.

Investor Verification Checklist

• TGA Certification: Verify the receipt of the TGA certificate of compliance by the end of fiscal 2005, as this is a key competitive advantage for international sales.
• Customer Concentration: Monitor the stability of relationships with the top two customers, who represent nearly 80% of revenue.
• Margin Trends: Assess whether the shift to powder products (lower margins) is a permanent structural change or a temporary mix fluctuation.
• Capital Expenditure ROI: Evaluate the operational efficiency gains and capacity utilization of the new Vista, California facility following its grand opening in May 2005.
• Legal Resolution: Track the status of the Novogen patent infringement lawsuit for potential settlement costs or litigation expenses.